VISLISI trial, a prospective clinical study allowing identification of a new metalloprotease and putative virulence factor from Staphylococcus lugdunensis

X. Argemi (1, 2) , G. Prevost (1, 2) , P. Riegel (1, 2) , D. Keller (1) , N. Meyer (1) , M. Baldeyrou (1) , N. Douiri (1) , N. Lefebvre (1) , K. Meghit (1) , C. Ronde Oustau (1) , D. Christmann (1, 2) , S. Cianferani (3) , J.M. Strub (3) , Y. Hansmann (1, 2)

1 HUS - Les Hôpitaux Universitaires de Strasbourg
2 Institut de bactériologie
3 DSA-IPHC - Département Sciences Analytiques et Interactions Ioniques et Biomoléculaires

Domaines: Chimie

X. Argemi, G. Prevost, P. Riegel, D. Keller, N. Meyer, et al.. VISLISI trial, a prospective clinical study allowing identification of a new metalloprotease and putative virulence factor from Staphylococcus lugdunensis. Clinical Microbiology and Infection, 2017, 23 (5), pp.334.e1 - 334.e8. ⟨10.1016/j.cmi.2016.12.018⟩. ⟨hal-01703142⟩